ADAPYAdaptimmune Therapeutics PLCvs its industry peers
A metric-by-metric comparison of Adaptimmune Therapeutics PLC against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAPYThis | — | — | — | — | 195.3%#1 | 37.8%#6 | -38.6%#4 | — | — | — | — | — |
| ABOS | $154M#9 | — | 1.8x#2 | — | — | -18.6%#10 | — | -138.7%#6 | -185.6%#3 | — | 31.1%#2 | — |
| ABPO | — | — | — | — | 50.0%#3 | 218.1%#1 | -4618.6%#8 | — | — | — | — | — |
| ABPWW | $116152#12 | 0.0x#1 | — | 0.6x#1 | 50.0%#3 | 218.1%#1 | -4618.6%#8 | — | — | — | -45.6%#7 | — |
| ACOG | $172M#7 | — | 3.0x#4 | 16.9x#6 | — | -39.8%#13 | -221.7%#5 | -36.0%#3 | — | — | -20.5%#6 | — |
| ADMA | $1.9B#2 | 12.2x#3 | 4.9x#5 | 3.8x#3 | 19.6%#5 | -25.7%#12 | 37.5%#1 | 37.6%#1 | 34.3%#1 | 5#1 | -52.2%#8 | — |
| ADPT | $3.6B#1 | — | 16.5x#7 | 12.9x#5 | 54.8%#2 | 62.7%#5 | -20.6%#3 | -27.5%#2 | -21.2%#2 | — | 108.8%#1 | — |
| AGEN | $249M#6 | 2.9x#2 | — | 2.2x#2 | 10.4%#6 | 98.7%#3 | -17.7%#2 | — | — | — | -1.1%#4 | — |
| AGMB | $433M#5 | — | — | — | — | — | — | — | — | — | — | — |
| AGTX | — | — | — | — | -100.0%#10 | 14.4%#9 | — | — | — | — | — | — |
| AIM | $4M#11 | — | 1.7x#1 | 41.4x#7 | -48.2%#8 | 19.4%#8 | -13254.5%#10 | -656.8%#7 | — | — | -97.0%#12 | — |
| ALEC | $164M#8 | — | 15.8x#6 | 7.8x#4 | -79.1%#9 | -20.2%#11 | -741.3%#6 | -1377.4%#8 | — | — | -17.8%#5 | — |
| ALGS | — | — | — | — | -39.5%#7 | 81.6%#4 | -4024.9%#7 | -76.1%#5 | — | — | -54.5%#9 | — |
| ALLO | $602M#4 | — | 2.2x#3 | — | -100.0%#10 | 25.9%#7 | — | -68.4%#4 | — | — | 15.6%#3 | — |
| ALVO | $950M#3 | — | — | — | — | — | — | — | — | — | -66.8%#10 | — |
| ALVOW | $100M#10 | — | — | — | — | — | — | — | — | — | -83.6%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-07-25.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice